AIP
IMVT icon

Arrowpoint Investment Partners’s Immunovant IMVT Stock Holding History

Arrowpoint Investment Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,714
Closed -$349K – 115
2025
Q4 		$349K Buy
+13,714
New +$306K 0.05% 82

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Arrowpoint Investment Partners's IMVT Position: Q1 2026 in Review

Arrowpoint Investment Partners sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 13,714 shares — an estimated $349K sold.

Arrowpoint Investment Partners first reported a position in IMVT in Q4 2025 and held it in 1 quarter. The position peaked at $349K in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Arrowpoint Investment Partners reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 13,714 Immunovant shares in Q1 2026, an estimated $349K.
  • Arrowpoint Investment Partners first reported a position in Immunovant in Q4 2025 and held it in 1 quarter.
  • Arrowpoint Investment Partners's Immunovant position peaked at $349K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.